Pasithea Therapeutics Corp. Warrant

Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on discovering, researching, and developing treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate, PAS-004, is a next-generation macrocyclic MEK inhibitor being developed for RASopathies including neurofibromatosis type 1 (NF1), MAPK pathway-driven tumors such as BRAF V600 and BRAF fusion tumors, and ETS2-driven diseases including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003 for amyotrophic lateral sclerosis, and it also intends to develop PAS-001 for schizophrenia. Incorporated in 2020, Pasithea Therapeutics Corp. is headquartered in Miami Beach, Florida.